| Characteristics | Frequency (N) | Percentage (%) |
|---|
| WHO clinical staging |
| I / II | 304 | 61.8 |
| III /IV | 188 | 38.2 |
| CD4 count |
| < 100 | 113 | 23.0 |
| 100–200 | 123 | 25.1 |
| 201–350 | 140 | 28.5 |
| > = 351 | 115 | 23.4 |
| Functional status |
| Working | 418 | 85.1 |
| Ambulatory /bed redden | 73 | 14.9 |
| Hemoglobin level |
| < 10 g/dl | 44 | 9.6 |
| > = 10 g/gl | 416 | 90.4 |
| BMI/MUAC |
| Underweight | 145 | 29.5 |
| Not Underweight | 347 | 70.5 |
| Eligible criteria |
| CD4 cell count | 199 | 40.5 |
| WHO stage | 49 | 10.0 |
| Both | 116 | 23.6 |
| Test & treat | 89 | 18.2 |
| Not recorded | 38 | 7.7 |
| Initial regimen |
| 1d = ZDV-3TC EFV | 11 | 2.2 |
| 1c = ZDV-3TC- NVP | 36 | 7.3 |
| 1e = TDF-3TC-EFV | 423 | 86.2 |
| 1f = TDF-3TF-NVP | 15 | 3.1 |
| Other | 6 | 1.2 |
| Past TB history |
| Yes | 7 | 1.4 |
| No | 483 | 98.6 |
